Media stories about Cerus (NASDAQ:CERS) have been trending somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cerus earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.109771741498 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Several research analysts have issued reports on CERS shares. BTIG Research reaffirmed a “hold” rating on shares of Cerus in a report on Thursday, January 25th. Zacks Investment Research cut shares of Cerus from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $5.00 target price on shares of Cerus in a report on Tuesday, January 23rd. Robert W. Baird reiterated a “buy” rating and issued a $5.00 price target on shares of Cerus in a research note on Friday, December 1st. Finally, BidaskClub upgraded shares of Cerus from a “strong sell” rating to a “sell” rating in a research note on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Cerus currently has a consensus rating of “Hold” and an average price target of $5.83.
Shares of Cerus (CERS) traded down $0.05 during midday trading on Friday, reaching $4.22. 1,121,451 shares of the company traded hands, compared to its average volume of 1,365,116. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.71 and a quick ratio of 3.11. Cerus has a 12 month low of $1.93 and a 12 month high of $5.43. The company has a market capitalization of $531.25, a price-to-earnings ratio of -7.15 and a beta of 2.22.
Cerus Company Profile
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.